Healthy Volunteer
Conditions
Keywords
Drug therapy
Brief summary
The purpose of this study is to assess the pharmacokinetics and safety of single- and multiple-dose of TAK-491 in healthy Chinese participants.
Detailed description
The drug being tested in this study is called TAK-491. TAK-491 is being tested to treat people who have hypertension. This study will look at the pharmacokinetics of TAK-491 in Chinese participants who take TAK-491. The study will enroll approximately 64 participants. The first 16 enrolled participants have been randomly assigned (by chance, like flipping a coin) to 1 of the 2 treatment groups: * TAK-491 40 mg * TAK-491 80 mg All participants will be asked to take 1 tablet at the same time on Day 1 and Day 4 to 10 during the study. The following 48 randomized participants will be randomly assigned (by chance, like flipping a coin) to 1 of the 3 treatment groups: * TAK-491 40 mg * TAK-491 80 mg * TAK-491 placebo All participants will be asked to take two tablets at the same time on Day 1 and Day 4 to 10 during the study. This single-center trial will be conducted in China. The overall time to participate in this study is approximately 52 days. Participants will be admitted in the clinic for the first 12 days, and will be contacted by telephone 14 days after last dose of study drug for a follow-up assessment.
Interventions
DRUGTAK-491
TAK-491 tablets
DRUGTAK-491 placebo
TAK-491 placebo-matching tablets
Sponsors
Takeda
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Is capable of understanding and complying with protocol requirements. 2. The participant or, when applicable, the legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures. 3. Is a healthy adult male or female of Chinese descent. 4. Is aged 18 to 45 years, inclusive, at the time of informed consent and first study medication dose. 5. Has a body mass index (BMI) greater than or equal to (\>=) 19.0 kilogram per square meter (kg/m\^2) and less than (\<) 24.0 kg/m\^2, inclusive at Screening. 6. Has clinical laboratory evaluations (including clinical chemistry \[fasted for at least 8 hours for the screening assessment\], hematology, and complete urinalysis) within the reference range for the testing laboratory, unless the results were deemed by the investigator to be not clinically significant at Screening and Check-in (Day -1). 7. Is willing to refrain from strenuous exercise, from 72 hours before Check-in (Day-1) until after Final Visit. 8. A female of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after the last dose of study drug.
Exclusion criteria
1. Has received any investigational compound within 30 days prior to Screening. 2. Has received TAK-491 in a previous clinical study or as a therapeutic agent. 3. Is an immediate family member, study site employee, or in a dependant relationship with a study site employee who is involved in the conduct of this study (example, spouse, parent, child, sibling) or may consent under duress. 4. Has history of uncontrolled, clinically significant manifestations of metabolic (including diabetes mellitus, hypercholesterolemia, or dyslipidemia), endocrine, hematologic, pulmonary, cardiovascular, gastrointestinal, neurological, rheumatologic, skin and subcutaneous tissue disorders, infectious, hepatic, renal, urologic, immunologic, psychiatric or mood disorders (including any past history of suicide attempt), or a history of lactose intolerance, which may impact the ability of the participant to participate or potentially confound the study results. 5. Has a known hypersensitivity to any component of the formulation of TAK-491 or other AII inhibitors or related compounds. 6. Has a positive urine drug result for drugs of abuse or breath alcohol test at Screening or Check-in (Day -1). 7. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening visit or is unwilling to agree to abstain from alcohol and drugs throughout the study. 8. Has taken any excluded medication, supplements, or food products. 9. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 30 days after participating in this study; or intending to donate ova during such time period. 10. Has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (that is, a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis frequent \[more than once per week\] occurrence of heartburn, or any surgical intervention \[example, cholecystectomy\]). 11. Has a history of cancer, except basal cell carcinoma which has been in remission for at least 5 years prior to Day 1. 12. Has positive test result for anti-Human immunodeficiency virus (HIV), anti- hepatitis C virus (HCV) antibodies, or for hepatitis B surface antigen (HBsAg) at Screening. 13. Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to Check-in (Day -1). Cotinine test is positive at Screening or Check-in (Day -1). 14. Has poor peripheral venous access. 15. Has donated or lost 450 milliliter (mL) or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 30 days prior to Day 1. 16. Has a Screening or Check-in (Day -1) abnormal (clinically significant) electrocardiogram (ECG). Entry of any participants with an abnormal (not clinically significant) ECG must be approved, and documented by signature by the principal investigator. 17. Has abnormal Screening or Check-in (Day -1) laboratory values that suggest a clinically significant underlying disease or participant with the following lab abnormalities: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) greater than (\>) 1.5 times the upper limits of normal. 18. Has a hemoglobin value \<12 gram per deciliter (g/dL) at Screening. 19. Has a systolic blood pressure \<110 and \>=160 millimeter of Mercury (mmHg) or a diastolic blood pressure \<60 and \>=100 mmHg at Screening or Check-in (Day -1).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose |
| Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | Day 10 pre-dose and at multiple time points (up to 24 hours) post-dose |
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose |
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | Day 10 pre-dose and at multiple time points (up to 24 hours) post-dose |
| AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose |
| AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | Day 10 pre-dose and at multiple time points (up to 24 hours) post-dose |
| Terminal Phase Elimination Half-life (T1/2) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose |
Countries
China
Participant flow
Recruitment details
Participants took part in the study at 1 investigative site in China from 17 November 2015 to 17 March 2017.
Pre-assignment details
Healthy Chinese participants were enrolled in the study in 2-parts, Open-label in which participants were allocated equally and randomly to TAK-491 40 milligram (mg) and TAK-491 80 mg and Double-blind in which participants were allocated equally and randomly to 1 of 3 regimens Placebo, TAK-491 40 mg, and TAK-491 80 mg.
Participants by arm
| Arm | Count |
|---|---|
| Open Label: TAK-491 40 mg TAK-491 40 mg, tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment. | 8 |
| Open Label: TAK-491 80 mg TAK-491 80 mg, tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment. | 8 |
| Double-blind: Placebo TAK-491 placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 as a double blinded treatment. | 16 |
| Double-blind: TAK-491 40 mg TAK-491 40 mg, tablet, orally, once daily and TAK-491 placebo-matching tablets, orally, once daily on Day 1 and Days 4 to 10 as a double blinded treatment. | 16 |
| Double-blind: TAK-491 80 mg TAK-491 80 mg, tablet, orally, once daily and TAK-491 placebo-matching tablets, orally, once daily on Day 1 and Days 4 to 10 as a double blinded treatment. | 16 |
| Total | 64 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Double-Blinded Treatment Period | Withdrawal by Subject | 0 | 0 | 1 | 0 | 1 |
Baseline characteristics
| Characteristic | Total | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: Placebo | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg |
|---|---|---|---|---|---|---|
| Age, Continuous | 29.9 years STANDARD_DEVIATION 5.19 | 28.8 years STANDARD_DEVIATION 4.4 | 30.3 years STANDARD_DEVIATION 4.98 | 33.0 years STANDARD_DEVIATION 5.07 | 27.4 years STANDARD_DEVIATION 4.19 | 29.7 years STANDARD_DEVIATION 5.63 |
| Body Mass Index (BMI) | 22.18 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 1.382 | 22.96 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 1.289 | 21.94 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 1.707 | 21.89 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 1.143 | 22.23 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 1.703 | 22.16 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 1.109 |
| Female Reproductive Status Having Childbearing Potential | 11 Participants | 3 Participants | 3 Participants | 1 Participants | 1 Participants | 3 Participants |
| Female Reproductive Status Male Participants | 53 Participants | 5 Participants | 5 Participants | 15 Participants | 15 Participants | 13 Participants |
| Female Reproductive Status Postmenopausal | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Female Reproductive Status Surgically Sterile | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Height | 170.2 centimeter (cm) STANDARD_DEVIATION 6.41 | 169.9 centimeter (cm) STANDARD_DEVIATION 6.66 | 165.3 centimeter (cm) STANDARD_DEVIATION 6.36 | 171.0 centimeter (cm) STANDARD_DEVIATION 6.07 | 170.4 centimeter (cm) STANDARD_DEVIATION 5.8 | 171.9 centimeter (cm) STANDARD_DEVIATION 6.75 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 64 Participants | 8 Participants | 8 Participants | 16 Participants | 16 Participants | 16 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment China | 64 participants | 8 participants | 8 participants | 16 participants | 16 participants | 16 participants |
| Sex: Female, Male Female | 11 Participants | 3 Participants | 3 Participants | 1 Participants | 1 Participants | 3 Participants |
| Sex: Female, Male Male | 53 Participants | 5 Participants | 5 Participants | 15 Participants | 15 Participants | 13 Participants |
| Smoking classification Current smoker | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Smoking classification Ex-smoker | 7 Participants | 0 Participants | 0 Participants | 2 Participants | 2 Participants | 3 Participants |
| Smoking classification Never smoked | 57 Participants | 8 Participants | 8 Participants | 14 Participants | 14 Participants | 13 Participants |
| Weight | 64.40 kilogram (kg) STANDARD_DEVIATION 6.619 | 66.23 kilogram (kg) STANDARD_DEVIATION 4.785 | 59.83 kilogram (kg) STANDARD_DEVIATION 4.951 | 64.09 kilogram (kg) STANDARD_DEVIATION 6.012 | 64.79 kilogram (kg) STANDARD_DEVIATION 7.916 | 65.69 kilogram (kg) STANDARD_DEVIATION 6.934 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 8 | 0 / 8 | 0 / 16 | 0 / 16 | 0 / 16 |
| other Total, other adverse events | 4 / 8 | 4 / 8 | 6 / 16 | 4 / 16 | 10 / 16 |
| serious Total, serious adverse events | 0 / 8 | 0 / 8 | 0 / 16 | 0 / 16 | 0 / 16 |
Outcome results
Primary
AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10
Time frame: Day 10 pre-dose and at multiple time points (up to 24 hours) post-dose
Population: PK set where Day 10 assessments were available. The PK set consisted of all participants who received study drug and had at least 1 measurable plasma concentration for TAK-536.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Open Label: TAK-491 40 mg | AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | 25087 h*ng/mL | Geometric Coefficient of Variation 21.5 |
| Open Label: TAK-491 80 mg | AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | 45320 h*ng/mL | Geometric Coefficient of Variation 14.7 |
| Double-blind: TAK-491 40 mg | AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | 21872 h*ng/mL | Geometric Coefficient of Variation 19.1 |
| Double-blind: TAK-491 80 mg | AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | 47993 h*ng/mL | Geometric Coefficient of Variation 31.8 |
Primary
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Population: The PK set consisted of all participants who received study drug and had at least 1 measurable plasma concentration for TAK-536.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Open Label: TAK-491 40 mg | AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 25905 hour*nanogram per milliliter (h*ng/mL) | Geometric Coefficient of Variation 27.3 |
| Open Label: TAK-491 80 mg | AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 50359 hour*nanogram per milliliter (h*ng/mL) | Geometric Coefficient of Variation 12.1 |
| Double-blind: TAK-491 40 mg | AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 23439 hour*nanogram per milliliter (h*ng/mL) | Geometric Coefficient of Variation 22.6 |
| Double-blind: TAK-491 80 mg | AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 45698 hour*nanogram per milliliter (h*ng/mL) | Geometric Coefficient of Variation 32.1 |
Primary
Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Population: The pharmacokinetic (PK) set consisted of all participants who received study drug and had at least 1 measurable plasma concentration for TAK-536.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Open Label: TAK-491 40 mg | Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 2877 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 25 |
| Open Label: TAK-491 80 mg | Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 6250 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 20.5 |
| Double-blind: TAK-491 40 mg | Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 2444 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 22.5 |
| Double-blind: TAK-491 80 mg | Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 5460 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 30.4 |
Primary
Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10
Time frame: Day 10 pre-dose and at multiple time points (up to 24 hours) post-dose
Population: PK set where Day 10 assessments were available. The PK set consisted of all participants who received study drug and had at least 1 measurable plasma concentration for TAK-536.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Open Label: TAK-491 40 mg | Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | 3070 ng/mL | Geometric Coefficient of Variation 4.6 |
| Open Label: TAK-491 80 mg | Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | 6019 ng/mL | Geometric Coefficient of Variation 29.5 |
| Double-blind: TAK-491 40 mg | Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | 2628 ng/mL | Geometric Coefficient of Variation 23.3 |
| Double-blind: TAK-491 80 mg | Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | 6226 ng/mL | Geometric Coefficient of Variation 19.9 |
Primary
Terminal Phase Elimination Half-life (T1/2) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Population: The PK set consisted of all participants who received study drug and had at least 1 measurable plasma concentration for TAK-536.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Open Label: TAK-491 40 mg | Terminal Phase Elimination Half-life (T1/2) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 11.18 hour | Geometric Coefficient of Variation 19.4 |
| Open Label: TAK-491 80 mg | Terminal Phase Elimination Half-life (T1/2) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 10.18 hour | Geometric Coefficient of Variation 24.1 |
| Double-blind: TAK-491 40 mg | Terminal Phase Elimination Half-life (T1/2) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 11.12 hour | Geometric Coefficient of Variation 16.9 |
| Double-blind: TAK-491 80 mg | Terminal Phase Elimination Half-life (T1/2) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 11.10 hour | Geometric Coefficient of Variation 18.9 |
Primary
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Population: The PK set consisted of all participants who received study drug and had at least 1 measurable plasma concentration for TAK-536.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Open Label: TAK-491 40 mg | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 3.03 hour |
| Open Label: TAK-491 80 mg | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 2.50 hour |
| Double-blind: TAK-491 40 mg | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 3.00 hour |
| Double-blind: TAK-491 80 mg | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 2.50 hour |
Primary
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10
Time frame: Day 10 pre-dose and at multiple time points (up to 24 hours) post-dose
Population: PK set where Day 10 assessments were available. The PK set consisted of all participants who received study drug and had at least 1 measurable plasma concentration for TAK-536.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Open Label: TAK-491 40 mg | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | 3.00 hour |
| Open Label: TAK-491 80 mg | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | 2.52 hour |
| Double-blind: TAK-491 40 mg | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | 3.49 hour |
| Double-blind: TAK-491 80 mg | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | 2.00 hour |